Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02786277 · ClinicalTrials.gov registry record · NA
Learning Alerts for Acute Kidney Injury
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 2,046
- Enrollment target
NCT02786277: Completed NA study, sponsored by Yale University.
NCT02786277 is a NA study that has completed, run by Yale University. The registered enrollment target is 2,046 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (46% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02786277, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,046 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether the use of uplift (also known as Conditional Average Treatment Effect - CATE) modeling to empirically identify patients expected to benefit the most from AKI alerting and to target AKI alerts to these patients will reduce the rates of AKI progression, dialysis, and mortality.
Primary Outcome
Progression of AKI is defined as the increase in KDIGO stage from the time of randomization to the present. For patients who are discharged, we will impute 14-day creatinine using the last observation carried forward method. Dialysis is defined as the receipt of hemodialysis, continuous renal replacement therapy, or peritoneal dialysis. Isolated ultrafiltration treatments will not be included. Mortality will be determined from hospital administrative records.
Interventions
- OTHER Alert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,046 participants |
| Start Date | 2024-02-15 |
| Est. Completion | 2025-05-03 |
| Phase | NA |
What the finished NCT02786277 record still lists
NCT02786277 is an interventional study that assigns participants to a tested intervention. Its 2,046 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (46% higher).
The record links to 0 conditions, and to 1 intervention - of which Alert is the first listed.
NCT02786277 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02786277 about?
NCT02786277 is a clinical study titled "Learning Alerts for Acute Kidney Injury". The primary objective of this study is to determine whether the use of uplift (also known as Conditional Average Treatment Effect - CATE) modeling to empirically identify patients expected to benefit the most from AKI alerting and to target AKI alerts to these patients will reduce the rates of AKI p...
What is the current status of trial NCT02786277?
This trial is currently completed. It is a NA study. The enrollment target is 2,046 participants. The study started on 2024-02-15. Estimated completion is 2025-05-03.
What interventions are being tested in trial NCT02786277?
The interventions under investigation include: Alert (OTHER).
Who is sponsoring clinical trial NCT02786277?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02786277's enrollment target sits among peer trials
2,046 52nd of 2000 higher than 1,949 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06833476 · 2,044 participants
TTVR STRONG Under Coverage With Evidence Development (CED) Study
- NCT05688982 · 2,049 participants · NA
MOLAR: Mapping Oral Health and Local Area Resources
- NCT05050084 · 2,050 participants · Phase 3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
- NCT05138718 · 2,041 participants
FDG an Myocardial Infarction: The PIAF Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI